Biomea Fusion Inc (BMEA)

$2.64 +0.28 (11.86%)
Market Cap 88.67M
Revenue (ttm) 0.00
Net Income (ttm) -138.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,505,370
Avg Vol 2,226,374
Day's Range N/A - N/A
Shares Out 37.57M
Stochastic %K 55%
Beta -0.23
Analysts Strong Sell
Price Target $19.78

Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. It's lead product candidate is icovamenib, is designed to be a bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes inclu...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 980 9099
Address:
900 Middlefield Road, 4th Floor, Redwood City, United States
Kid_Shelleen
Kid_Shelleen Jun. 16 at 7:48 PM
$BMEA Here's what you want to know. https://finviz.com/quote.ashx?t=BMEA&ty=c&ta=1&p=d
0 · Reply
BobBijawklah
BobBijawklah Jun. 16 at 7:21 PM
$BMEA so just some numbers there 20k cases of refractory relapsed AML in USA. gilternib has a cost of 40k for a 90 day supply . It is the only approved treatment in that indication. So you can easily see how BMF500 could be anwywere from 200 million to 500 million in sales . Like i said their share price is indictive of the value of this asset at this stage in development nothing else. So when you consider the potential value of the diabetes and obesity you can see how the stock price is upwards is truly anemic in comparison to the potential revenues in all of their assets.
0 · Reply
mrd4
mrd4 Jun. 16 at 7:08 PM
$BMEA watch now!
1 · Reply
mrd4
mrd4 Jun. 16 at 6:44 PM
$BMEA I actually think we might see the 3s today. It’s climbing on an analysis with a PT of 16. Power hour could be amazing.
0 · Reply
BobBijawklah
BobBijawklah Jun. 16 at 6:32 PM
$BMEA so that is the reason for the jump. so if they chose to scrap a drug that is best i class and only has 1 competing drug in that class that is far less superior think of the value of the assets for diabetes and obesity. You will look back in 10 years and kick yourself in the nuts for not buying more
1 · Reply
BobBijawklah
BobBijawklah Jun. 16 at 6:30 PM
$BMEA Giliternib is the only approved agent in Relapse refractory AML . During that trial no complete responses were had. OS was 2 months. BMF500 1 confirmed complete response a second ongoing cancer free response. with a 3.8 OS essentially doubling the approved standard of care. Alone that drug is worth 2.50 a share possibly more.
0 · Reply
Rob88ynn
Rob88ynn Jun. 16 at 6:23 PM
$BMEA real quiet in here
1 · Reply
mrd4
mrd4 Jun. 16 at 4:25 PM
$BMEA It’s only now that the real volume has come in, paving the way for a rally.
0 · Reply
Rob88ynn
Rob88ynn Jun. 16 at 4:13 PM
$BMEA volume accelerating - anyone know what’s going on?
0 · Reply
mrd4
mrd4 Jun. 16 at 4:07 PM
$BMEA new TP 16🚀🚀
0 · Reply
Latest News on BMEA
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

Jun 13, 2025, 6:45 AM EDT - 3 days ago

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

May 14, 2025, 4:05 PM EDT - 4 weeks ago

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

May 5, 2025, 4:05 PM EDT - 6 weeks ago

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Apr 1, 2025, 4:01 PM EDT - 2 months ago

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mar 31, 2025, 4:10 PM EDT - 2 months ago

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Biomea Fusion Announces Leadership Transition

Mar 25, 2025, 7:00 PM EDT - 2 months ago

Biomea Fusion Announces Leadership Transition

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Mar 24, 2025, 8:30 AM EDT - 3 months ago

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2025, 8:00 AM EST - 3 months ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Feb 27, 2025, 8:00 AM EST - 3 months ago

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

Dec 17, 2024, 10:41 AM EST - 6 months ago

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Dec 17, 2024, 8:10 AM EST - 6 months ago

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Dec 16, 2024, 6:15 PM EST - 6 months ago

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 12, 2024, 5:02 PM EST - 6 months ago

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Dec 9, 2024, 4:01 PM EST - 6 months ago

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Dec 6, 2024, 8:00 AM EST - 6 months ago

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Nov 3, 2024, 11:00 AM EST - 8 months ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Biomea Fusion Inc Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 31, 2024, 11:00 AM EDT - 8 months ago

Biomea Fusion Inc Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

Oct 30, 2024, 4:00 PM EDT - 8 months ago

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

Oct 29, 2024, 4:46 PM EDT - 8 months ago

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

An Investigation Has Been Launched Into Whether Biomea Fusion Inc Committed Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 29, 2024, 11:00 AM EDT - 8 months ago

An Investigation Has Been Launched Into Whether Biomea Fusion Inc Committed Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

The Schall Law Firm Urges Shareholders To Take Part In An Inquiry Into Biomea Fusion, Inc. For Fraud

Oct 28, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Urges Shareholders To Take Part In An Inquiry Into Biomea Fusion, Inc. For Fraud

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 26, 2024, 11:00 AM EDT - 8 months ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Reach Out To The Schall Law Firm

Oct 22, 2024, 11:00 AM EDT - 8 months ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Reach Out To The Schall Law Firm

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

Oct 21, 2024, 9:00 AM EDT - 8 months ago

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 20, 2024, 11:00 AM EDT - 8 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

The Schall Law Firm Urges Shareholders To Join An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Oct 19, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Urges Shareholders To Join An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Oct 18, 2024, 11:00 AM EDT - 8 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Oct 17, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy

Oct 15, 2024, 4:05 PM EDT - 8 months ago

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Impacted Investors Should Contact The Schall Law Firm

Oct 8, 2024, 11:00 AM EDT - 8 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Impacted Investors Should Contact The Schall Law Firm

Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

Oct 7, 2024, 9:00 AM EDT - 9 months ago

Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Oct 6, 2024, 11:00 AM EDT - 9 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

Oct 4, 2024, 11:00 AM EDT - 9 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

The Schall Law Firm Encourages Shareholders To Help Look Into Biomea Fusion, Inc. For Securities Related Infractions

Oct 3, 2024, 11:00 AM EDT - 9 months ago

The Schall Law Firm Encourages Shareholders To Help Look Into Biomea Fusion, Inc. For Securities Related Infractions

Investors Are Invited To Join The Schall Law Firm In An Investigation Into Biomea Fusion Inc For Possible Securities Fraud

Oct 2, 2024, 11:00 AM EDT - 9 months ago

Investors Are Invited To Join The Schall Law Firm In An Investigation Into Biomea Fusion Inc For Possible Securities Fraud

Kid_Shelleen
Kid_Shelleen Jun. 16 at 7:48 PM
$BMEA Here's what you want to know. https://finviz.com/quote.ashx?t=BMEA&ty=c&ta=1&p=d
0 · Reply
BobBijawklah
BobBijawklah Jun. 16 at 7:21 PM
$BMEA so just some numbers there 20k cases of refractory relapsed AML in USA. gilternib has a cost of 40k for a 90 day supply . It is the only approved treatment in that indication. So you can easily see how BMF500 could be anwywere from 200 million to 500 million in sales . Like i said their share price is indictive of the value of this asset at this stage in development nothing else. So when you consider the potential value of the diabetes and obesity you can see how the stock price is upwards is truly anemic in comparison to the potential revenues in all of their assets.
0 · Reply
mrd4
mrd4 Jun. 16 at 7:08 PM
$BMEA watch now!
1 · Reply
mrd4
mrd4 Jun. 16 at 6:44 PM
$BMEA I actually think we might see the 3s today. It’s climbing on an analysis with a PT of 16. Power hour could be amazing.
0 · Reply
BobBijawklah
BobBijawklah Jun. 16 at 6:32 PM
$BMEA so that is the reason for the jump. so if they chose to scrap a drug that is best i class and only has 1 competing drug in that class that is far less superior think of the value of the assets for diabetes and obesity. You will look back in 10 years and kick yourself in the nuts for not buying more
1 · Reply
BobBijawklah
BobBijawklah Jun. 16 at 6:30 PM
$BMEA Giliternib is the only approved agent in Relapse refractory AML . During that trial no complete responses were had. OS was 2 months. BMF500 1 confirmed complete response a second ongoing cancer free response. with a 3.8 OS essentially doubling the approved standard of care. Alone that drug is worth 2.50 a share possibly more.
0 · Reply
Rob88ynn
Rob88ynn Jun. 16 at 6:23 PM
$BMEA real quiet in here
1 · Reply
mrd4
mrd4 Jun. 16 at 4:25 PM
$BMEA It’s only now that the real volume has come in, paving the way for a rally.
0 · Reply
Rob88ynn
Rob88ynn Jun. 16 at 4:13 PM
$BMEA volume accelerating - anyone know what’s going on?
0 · Reply
mrd4
mrd4 Jun. 16 at 4:07 PM
$BMEA new TP 16🚀🚀
0 · Reply
Maclown
Maclown Jun. 16 at 3:39 PM
$BMEA fucked me I bought it at 2,80 fml
1 · Reply
Maclown
Maclown Jun. 16 at 3:38 PM
$BMEA when will it hit 3 dollar ??
1 · Reply
mrd4
mrd4 Jun. 16 at 2:39 PM
$BMEA Now I’ve loaded up properly. An increased price target, a drop on Friday, and good volume is a strong combination.
0 · Reply
CBARRR8
CBARRR8 Jun. 16 at 2:08 PM
$BMEA I figured all those posting how the shorts had run out of shares to short, was one gigantic set up.
0 · Reply
aquira
aquira Jun. 16 at 2:07 PM
$BMEA freaking frustrating. my average is 2.38 so really frustrated
0 · Reply
hashbridges
hashbridges Jun. 16 at 2:05 PM
$BMEA Shorts are probably in control for a bit which is why I pushed out a lot of my calls on top of holding the shares. When the next real news hits, this goes up 1-200%. Until then shorts will try to pick up pennies in front of the steamroller. That's just the way life works.
0 · Reply
Rob88ynn
Rob88ynn Jun. 16 at 1:59 PM
$BMEA wow, this is a pos
0 · Reply
nf04
nf04 Jun. 16 at 1:57 PM
$BMEA should be a good environment to move up a little, the whole market is squeezing up this morning; just $XBI needs to get it a little together, probably $SRPT taking it down with it.
0 · Reply
nf04
nf04 Jun. 16 at 1:48 PM
$BMEA they somehow found some shares to short, probably a small short seller entering at this level; maybe squeezing them can provide some fuel https://www.iborrowdesk.com/report/bmea
0 · Reply
Rob88ynn
Rob88ynn Jun. 16 at 1:46 PM
$BMEA why the volume and such little price movement
0 · Reply
mrd4
mrd4 Jun. 16 at 1:39 PM
$BMEA It was exactly like this when it started, running at 60% with this type of volume. One needs to be alert here.
0 · Reply
Rob88ynn
Rob88ynn Jun. 16 at 1:36 PM
$BMEA big volume
0 · Reply